Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VulVaccin: Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL
2023-506792-94-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Jan 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in HPV-related vulvar intraepithelial neoplasia comparing Gardasil 9 adjuvant vaccination with Placebo (0.9% sodium chloride) (2 arms). Primary endpoint: Clinical recurrence rate of vulvar HSIL at 24 months. Planned start Jan 2024; status: authorised.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
HPV-related vulvar intraepithelial neoplasia
Beyond the preview
Go deeper on 2023-506792-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506792-94-00.